drugset / Trial / NCT06967272
PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The Phase II clinical trial of the oral hexavalent reassortant rotavirus attenuated live vaccine (Vero Cells) will be conducted in infants aged 6 to 12 weeks. This study will evaluate the immunogenicity and safety of the investigational vaccine in healthy infants through a randomized, double-blind, active-controlled trial.
Timeline
- Start
- 2025-01-20
- Primary completion
- 2026-06-15
- Completion
- 2026-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | hexavalent reassortant rotavirus attenuated live vaccine | Vaccine | — | Oral |
| Comparator | pentavalent reassortant rotavirus attenuated live vaccine | Unknown | — | Oral |